Heterocyclic Compounds

Matches 401 - 450 out of 2,430	< 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 >

Document	Document Title
WO/2005/016351A1	NOVEL USE OF CANNABINOID RECEPTOR AGONIST An inhibitor for inflammatory cellular infiltration in the respiratory tract, inhibitor for hyperirritability in the respiratory tract, muciparous inhibitor, or bronchodilator which contains as an active ingredient a compound selected fr...
WO/2005/011611A2	BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS This invention is directed to novel bicyclic compounds, to the uses of these compounds in various medicinal applications, including treating disorders amenable to treatment by peptidyl deformylase inhibitors such as treatment of bacteria...
WO/2005/000406A2	TREATMENT OF AMYLOID- AND EPILEPTOGENESIS-ASSOCIATED DISEASES Methods of treating or preventing an amyloid-related disease in a subject by administering to a subject a therapeutic amount of a compound of the invention are described. Also included are methods for inhibiting epileptogenesis in a subj...
WO/2004/112575A2	GENE AMPLIFICATION AND OVEREXPRESSION IN CANCER There are disclosed methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers in mammals, for example, humans, utilizing a gene, which is amplified in many types of cancer. The amplified genes, their exp...
WO/2004/110986A1	BENZAMIDE DERIVATIVE OR SALT THEREOF A compound which functions to inhibit capsaicin receptor VR1 activation and is useful as a therapeutic agent for, e.g., various pains including inflammatory pain and neurogenic pain, migraine, cluster headache, and bladder diseases inclu...
WO/2004/111022A1	3-(1,1-DIOXOTETRAHYDRO-1,2-THIAZIN-2-YL) or 3-(1,1-DOXO-ISOTHIAZOLIDIN-2YL) SUBSTITUTED BENZAMIDE COMPOUNDS AS ASP2 INHIBITORS The present invention relates to hydroxyethylene compounds of formula (I); having A sp2 (β-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treat...
WO/2004/101539A1	CYCLIC SULFONAMIDES FOR INHIBITION OF GAMMA-SECRETASE Compounds of formula (I) inhibit the processing of APP by gamma-secretase, and hence are useful in the treatment or prevention of Alzheimer's disease.
WO/2004/101538A1	CYCLOHEXYL SULPHONES AS GAMMA-SECRETASE INHIBITORS Compounds of formula (I): inhibit gamma-secretase and hence find use in treatment or prevention of Alzheimer's disease.
WO/2004/101559A1	FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands and methods f...
WO/2004/096795A2	C-FMS KINASE INHIBITORS The invention is directed to compounds of formulae (I), (II) and (III), wherein A, R1, R2, R3, R4, X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that...
WO/2004/094382A1	MUSCARINIC AGONISTS The present invention relates to compounds of Formula (I): which are agonists of the M-1 muscarinic receptor.
WO/2004/094396A2	DIHYDROTHIAZINE PRODRUGS OF THIAZOLIUM AGENTS Provided are compounds of the formula (and pharmaceutically acceptable salts thereof): (formula I) wherein: R is hydrogen, methyl, hydroxymethyl or &agr -hydroxyethyl; Rl and R2 are independently selected from hydrogen, C1-C6 alkyl, C1-C...
WO/2004/091613A2	SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS Phenyl acetamide compounds are described, including compounds of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R3-R6, R11, B, Y and W are set forth in the specification. The compounds of the inven...
WO/2004/092116A1	BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical...
WO/2004/085431A1	PROSTAGLANDIN ANALOGS AS EP4 RECEPTOR ANTAGONISTS This invention relates to potent selective agonists of formula (I) of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intr...
WO/2004/085430A1	PROSTAGLANDIN ANALOGS AS EP4 RECEPTOR AGONISTS This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressur...
WO/2004/076402A1	ARYLCYCLOALKYL DERIVATIVES WITH BRANCHED SIDE CHAINS AS PPAR RECEPTOR MODULATORS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS The invention relates to arylcycloalkyl derivatives with branched side chains, in addition to their physiologically compatible salts and physiologically functional derivatives. The invention relates to compounds of formula (I), in which ...
WO/2004/065366A1	2.4-DIHALOGEN-6-(C2-C3-ALKYL)-PHENYL SUBSTITUTED TETRAMIC ACID DERIVATIVES The invention relates to novel 2.4-dihalogen-6-(C2-C3-alkyl)-phenyl substituted tetramic acid derivatives of formula (I), wherein A, B, D, G, X, Y and Z have the above mentioned meaning. The invention also relates to several methods and ...
WO/2004/063163A1	1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS Compounds of Formula (I) wherein R1, R2 R3, R4, R5, R6, and X are as defiend herein for Formula (IA) and Formula (IB), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods o...
WO/2004/060881A1	1,3-BENZOTHIAZINONE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF As a preventive/remedy for circulatory diseases, bone/joint diseases, infectious diseases, inflammatory diseases, kidney diseases and so on having a high safety and excellent effects of inhibiting cell death and binding to MIF, it is int...
WO/2004/050619A1	HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE The present invention relates to novel hydroxyethylamine compounds of formula (I): (I) having Asp2 (-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in ...
WO/2004/050623A1	METHODS FOR PREPARING PHENYLALKYNE DERIVATIVES Methods of making substituted phenylalkynes of formula (I).
WO/2004/046119A1	SUBSTITUTED ARALKYL DERIVATIVES The present invention relates to novel substituted aralkyl derivatives of the general formula (I) & (IIIa), their derivatives, their analogs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically accepta...
WO/2004/043940A1	PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES The present invention is directed to phenylalanine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptid...
WO2003062388A9	INHIBITION OF RNA FUNCTION Inhibition of RNA function, and treatment or control of associated diseases or conditions, e.g. infectious diseases such as viruses and viral infections (including HIV) and microbial infections, is inhibited by the use contacting of the ...
WO2003026563A9	CONJUGATED ANTI-PSYCHOTIC DRUGS AND USES THEREOF Novel chemical conjugates of anti-psychotic drugs and organic acids, uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic ac...
WO/2004/031134A1	PROCESS FOR MAKING SUBSTITUTED ARYL SULFONAMIDES USING AN INDIUM BASED CATALYST SYSTEM A process for making substituted aryl sulfonamides by sulfamoylation of an activated aromatic compound using an indium compound as a catalyst.
WO/2004/028538A1	SMALL ORGANIC MOLECULES THAT INCREASE THE ACTIVITY OF GELATINASE A IN OCULAR CELLS Small organic molecules capable of effecting a 'pharmacological trabeculocanalotomy' in an eye by means of reducing juxtacanalicular meshwork as a barrier to outflow of aqueous. The small organic molecules increase Gelatinase A activity ...
WO/2004/029672A2	TRANSIENT OPTICAL STATE CHANGE MATERIALS USEFUL IN COPY-PROTECTED COMPACT DISCS Phenothiazole compounds being substituted in at least the 3 and 7 positions with electron donating and electron withdrawing moeties. These include those shown in figure 1. These are useful in providing copy-protection for optical data st...
WO/2004/018428A1	ANTIBACTERIAL BENZOIC ACID DERIVATIVES The invention provides antimicrobial agents and methods of using the agents for sterilization, sanitation, antisepsis, disinfection, and treatment of infections in mammals.
WO/2004/018415A1	SULFONAMIDE DERIVATIVES, INSECTICIDES FOR AGRICULTURAL AND HORTICULTURAL USE, AND USAGE THEREOF Sulfonamide derivatives represented by the general formula (1) or salts thereof; insecticides for agricultural and horticultural use containing the same as the active ingredient; and usage thereof: (1) [wherein A is optionally substitute...
WO/2004/018414A2	ANTIBACTERIAL AGENTS The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof, wherein X=NH Y=CO, CS, -C(=N-CN) or X and Y together form an alkene, or C3-C5 cycloalkyl; R1 is -COOH; R2 is an electron withdrawing g...
WO/2004/014389A1	3,4-DIHYDROQUINOLIN-2-ONE, 5,6-FUSED OXAZIN-3-ONE, AND 5,6-FUSED THIAZIN-3-ONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS This invention provides compounds'defined by Formula I or a pharmaceutically acceptable salt thereof,wherein Rt, Q, Y1, Y5, Y6, Y8, R2, R2a, and R4 are as defined in the specification. The invention also provides pharmaceutical compositi...
WO/2004/014388A1	6,6-FUSED HETEROARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS This invention provides compounds defined by Formula (I) or a pharmaceutically acceptable salt thereof, wherein R?l¿, Q, Y?l¿, Y?2¿, Y?3Y¿, R?2a¿, R?2b¿, R?5¿, and n are as defined in the specification. The invention also provides...
WO/2004/013113A1	SUBSTITUTED THIAZINES AS MATERIAL PROTECTING AGENTS The invention relates to novel thiazines of formula (I), wherein the substituents R1 to R7 have the designation cited in the description, and to the metallic salts and acid addition compounds thereof. Said novel thiazines have an excelle...
WO/2004/013111A1	2-SUBSTITUTED BICYCLIC BENZOHETEROCYCLIC COMPOUNDS AND THEIR USE AS SODIUM CHANNEL BLOCKERS This invention relates to a method of treating disorders responsive to the blockade of sodium ion channels using novel 2-substituted bicyclic benzoheterocyclic compounds of Formula I, or a pharmaceutically-acceptable salt or solvate ther...
WO/2004/009530A1	PROCESS FOR PRODUCTION OF HIGH-PURITY ENAMINES A process for the production of compounds represented by the general formula (3) and having high purity: (3) [wherein R1 is C1-6 alkyl or the like and R2 is hydrogen or the like, or R1 and R2 may be united to form C1-6 alkylene; and R3 a...
WO/2004/000322A1	THIAZINE AND OXAZINE DERIVATIVES AS MMP-13 INHIBITORS FOR TREATING ARTHRITIS A compound selected from those of formula (I): wherein: • X1, X2, and X3 represent nitrogen or -CR3 in which R3 represents hydrogen, alkyl, amino, alkylamino, dialkylamino, hydroxy, alkoxy, or halogen, • Gl represents oxygen or S(O)p...
WO/2004/000321A1	THIAZINE AND OXAZINE DERIVATIVES AS MMP-13 INHIBITORS FOR TREATING ARTHRITIS A compound selected from those of formula (I) wherein: X¿1?, X¿2? and X¿3? represent nitrogen or -CR¿3? in which R¿3? represents hydrogen, alkyl, amino, alkylamino, dialkylamino, hydroxy, alkoxy, or halogen, G¿1? represents oxygen ...
WO/2003/107331A1	MATERIALS FOR OPTICAL MEDIUM COPY-PROTECTION TRANSIENTLY REACTING TO A READER BEAM A method and system for providing copy-protected optical medium using transient optical state change security materials capable of changing optical state and software code to detect such change in optical state.
WO/2003/105811A2	CONTROLLED RELEASE COMPOSITIONS AND METHODS FOR USING SAME Pharmaceutical preparations adapted for mucosal delivery of a pharmacologically effective dose of a pharmacologically active agent to a mammal, said pharmaceutical preparation comprising microcapsules adapted to provide controlled releas...
WO/2003/103569A2	TOLUIDINE BLUE O DRUG SUBSTANCE AND USE THEREOF FOR IN VIVO STAINING AND CHEMOTHERAPEUTIC TREATMENT OF DYSPLASTIC TISSUES The invention comprises an improved process for preparing TBO drug products includes the steps: (1) synthesising an indamine; (2) converting said indamine into an S-indaminyl thiosulfate; and (3) adding an oxidizing catalyst agent, compl...
WO/2003/099800A1	AN IMPROVED PROCESS FOR THE PREPARATION OF BICYCLIC ANTIDIABETIC AGENTS The present invention relates to an improved process for the preparation of antidiabetic compounds having the formula (1). where R represents (C1-C6)alkyl group, X represents sulphur or oxygen atom
WO/2003/097618A1	MORPHOLINYLMETHYLUREAS CCR-3 RECEPTOR ANTAGONISTS Compounds of formula (I'): (I); wherein: R1 represents substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; X represents -(CRkaRkb)k-; Rka and Rkb are each independently hydrogen or C1-6alkyl; k is 0-5; Y represe...
WO/2003/090782A1	CELL DEATH INHIBITOR A cell death inhibitor which contains a substance capable of binding to macrophage migration inhibitory factor and is useful as a preventive/remedy for heart diseases, neurodegenerative diseases, cerebrovascular diseases, central nerve i...
WO/2003/091202A1	DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAIING THE COMPOUNDS AS THE ACTIVE INGREDIENT Diketohydrazine derivatives represented by the following general formula (I) (wherein each symbol is as defined in the description) and pharmaceutically acceptable salts thereof: (I) Because of having a cysteine protease inhibitory activ...
WO/2003/084927A1	HALOALKENES, PROCESS FOR PRODUCTION THEREOF, AND PEST CONTROLLERS CONTAINING THE SAME Haloalkenes represented by the general formula (I) which are useful as pest controllers: (I) wherein X1 and X2 are each halogeno; Y is hydrogen or halogeno; n is 0 to 5; and Q is (1) a heterocyclic group selected from among thienyl, fury...
WO/2003/072567A1	NOVEL FUSED RING COMPOUNDS, AND THEIR USE AS CATIONIC PHOTOINITIATORS Compounds of formula (I) [in which: R1 represents a direct bond, an oxygen atom, a group >CH2, a sulphur atom, a group >C=O, a group -(CH2)2- or a group of formula -N-Ra, where Ra is hydrogen or an alkyl; R4, R5, R6 and R7 are each hydro...
WO/2003/070277A1	ANTIPRURITICS It is intended to provide antipruritics (drugs to control itching, antiitch agents and drugs to stop itching). It is found out that a compound having a cannabinoid receptor agonism shows an antipruritic effect.
WO/2003/066612A1	NOVEL POLYMORPHIC FORMS OF BICYCLIC ANTIDIABETIC AGENTS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM This invention relates to novel polymorphic / pseudopolymorphic forms of arginine salt of 3-[4-[2-(3,4-dihydro-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2- ethoxypropanoic acid, preferably, L- arginine salt of (2S) 3-[4-[2-(3,4-dihydro-1,4-be...

Matches 401 - 450 out of 2,430	< 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 >